Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review

[1] Dutta A(2011)From free entry to patent protection: welfare implications for the Indian pharmaceutical industry Rev Econ Stat 93 160-178

[2] Smith RD(2009)Trade, TRIPS, and pharmaceuticals Lancet. 373 684-691

[3] Correa C(2016)Trans-Pacific partnership provisions in intellectual property, transparency, and investment chapters threaten access to medicines in the US and elsewhere PLoS Med 13 e1001970-514

[4] Oh C(2006)Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India Am Econ Rev 96 477-182

[5] Baker B(2009)Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-plus proposal Health Policy 91 174-393

[6] Chaudhuri S(2017)The impacts of TRIPS on the pharmaceutical regulation and pricing of drugs in Bangladesh: in search of policy direction Int J Law Manag 59 376-677

[7] Goldberg PK(2010)Impact on access to medicines from TRIPS-plus: a case study of Thai-US FTA Southeast Asian J Trop Med Public Health 41 667-85

[8] Gia P(2012)The price of medicines in Jordan: the cost of trade-based intellectual property J Generic Med 9 75-81

[9] Akaleephan C(2015)Investigating the effect of data exclusivity on the pharmaceutical sector in Jordan Jordan J Pharm Sci 8 70-518

[10] Wibulpolprasert S(2007)Pricing and patents of HIV/AIDS drugs in developing countries Appl Econ 39 505-135

[1] Dutta A(2011)From free entry to patent protection: welfare implications for the Indian pharmaceutical industry Rev Econ Stat 93 160-178

[2] Smith RD(2009)Trade, TRIPS, and pharmaceuticals Lancet. 373 684-691

[3] Correa C(2016)Trans-Pacific partnership provisions in intellectual property, transparency, and investment chapters threaten access to medicines in the US and elsewhere PLoS Med 13 e1001970-514

[4] Oh C(2006)Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India Am Econ Rev 96 477-182

[5] Baker B(2009)Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-plus proposal Health Policy 91 174-393

[6] Chaudhuri S(2017)The impacts of TRIPS on the pharmaceutical regulation and pricing of drugs in Bangladesh: in search of policy direction Int J Law Manag 59 376-677

[7] Goldberg PK(2010)Impact on access to medicines from TRIPS-plus: a case study of Thai-US FTA Southeast Asian J Trop Med Public Health 41 667-85

[8] Gia P(2012)The price of medicines in Jordan: the cost of trade-based intellectual property J Generic Med 9 75-81

[9] Akaleephan C(2015)Investigating the effect of data exclusivity on the pharmaceutical sector in Jordan Jordan J Pharm Sci 8 70-518

[10] Wibulpolprasert S(2007)Pricing and patents of HIV/AIDS drugs in developing countries Appl Econ 39 505-135